Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
FRLN was delisted on the 16th of February, 2024.
16 hedge funds and large institutions have $91.6M invested in Freeline Therapeutics Holdings plc American Depositary Shares in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 4 closing their positions.
16% less funds holding
Funds holding: 19 → 16 (-3)
36% less capital invested
Capital invested by funds: $144M → $91.6M (-$52.4M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$137K |
| 2 |
Morgan Stanley
New York
|
+$117K |
| 3 |
Legal & General Group
London,
United Kingdom
|
+$20.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.23M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$1.94M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$549K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$210K |
| 5 |
Goldman Sachs
New York
|
-$207K |
FRLN Hedge Fund Activity: Q2 2021 in Review
16 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) for Q2 2021, worth a combined $91.6M — down 36% from $144M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FRLN and 1 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $137K. The largest seller was Wellington Management Group, cutting an estimated $2.23M.
- 16 institutional investors held Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) as of Q2 2021, down from 19 in Q1 2021.
- Funds reported $91.6M of Freeline Therapeutics Holdings plc American Depositary Shares stock for Q2 2021, down 36% quarter-over-quarter.
- 1 fund opened new Freeline Therapeutics Holdings plc American Depositary Shares positions in Q2 2021 and 4 closed out, a net change of -3 holders.
- The largest Freeline Therapeutics Holdings plc American Depositary Shares buyer in Q2 2021 was Citadel Advisors, an estimated $137K added.
- The largest Freeline Therapeutics Holdings plc American Depositary Shares seller in Q2 2021 was Wellington Management Group, an estimated $2.23M sold.
Based on aggregated 13F filings for Q2 2021.